Moderna (MRNA) Stock Price Up 4% as Trump Talks about Possible COVID-19 Vaccine This Year

UTC by Christopher Hamman · 3 min read
Moderna (MRNA) Stock Price Up 4% as Trump Talks about Possible COVID-19 Vaccine This Year
Photo: Shutterstock

Moderna (MRNA) stock price is up as U.S. President Donald Trump has indicated that there could be a working COVID-19 vaccine by the end of the year.

Moderna Inc (NASDAQ: MRNA) stock price has gone up by 4.22%. The prices went up at Friday’s close and are still up by about 2% in the pre-market. This northwards move comes as U.S. President Donald Trump has indicated that there could be a possible vaccine for COVID-19 later this year.

As at the time of writing, Moderna (MRNA) stock price is $48.90 (+2.02%) in the pre-market.

Sources say that the U.S. President made this known in a virtual Townhall on Sunday. In the Townhall, the U.S. President said several important things. Trump indicated that his administration was pushing the U.S. medical infrastructure. He said:

“We are pushing supply lines. We don’t even have the final vaccine.”

He also indicated that many companies are close to a cure. He also added:

“We are very confident that we are going to have a vaccine at the end of the year, by the end of the year.”

Although the U.S. and other countries have failed to make a great headstart, there seems to be light at the end of the tunnel. Many coronavirus vaccines are in trials. Most of them hold promise to b effective. Moderna’s mRNA-1273 is one of those. mRNA-1273 is supposed to go into phase-2 human trials by September. Phase-1 trials are currently underway.

Moderna (MRNA) Stock Price Up as It Increases Capacity

The good news is that Moderna is developing the manufacturing capacity for about a billion units of its vaccine. Moderna recently announced a deal with Lonza Group AG SWX (LONN) in this regard.

The billion unit capacity also comes at a time when governments the world over are easing the initial movement restrictions. There is going to be a rise in infections worldwide.

This readiness indicates yet to be disclosed positive news on the success of the trials. Though a final version of the vaccine may take years, successful trials will allow for a new paradigm. One in which rapid solutions could be found in less time than previously thought.

New Records Are Set

Vaccines take on an average of about 36 months to develop. Moderna has brought a new method of vaccine production. The messenger RNA or (m-RNA) technique has hitherto been unstable. Moderna intends to use RNA-based vaccines which may just be a first among many approaches.

As all of this occurs, the world economy seems to continue lurching from one end to the other. It also indicates that barring a vaccine with absolute efficacy, there would be no return to normal.

The solution to the current situation may lie in the hands of the geniuses who come up with solutions anytime humans encounter new problems.

Some of these geniuses could be found at companies like Moderna.

Business News, Market News, News, Stocks, Wall Street
Related Articles